Elevated sST2 associates with cardiac involvement and declines after treatment in newly diagnosed patients with idiopathic inflammatory myopathies
Authors' conclusion
sST2 is elevated in early IIM and closely associated with cardiac biomarkers and CMR-verified cardiac inflammation.
Study context
- Population
- Patients with newly diagnosed or established idiopathic inflammatory myopathies (IIM), with healthy controls (HC) and rheumatoid arthritis (RA) patients
- Exposure
- Newly diagnosed IIM vs established IIM, HC and RA
- Newly diagnosed IIMn = 34
- Established IIMn = 109
- Outcome
- Serum sST2 levels and their longitudinal profile in IIM and CI
Methodological detailslongitudinal, cross-sectional cohort, age and gender matched healthy controls
- Longitudinal
- Cross-sectional cohort
- Age and gender matched healthy controls
Main finding
As reported in the abstract
sST2 levels at diagnosis
- sST2 highest at diagnosis, decreased significantly by 6 months, and remained lower during follow-up
- IIM patients with active cardiac magnetic resonance (CMR)-verified CI had significantly higher sST2 than those without ongoing CI
- Newly diagnosed IIM vs HC: P < 0.0001
- Newly diagnosed IIM vs Established IIM: P < 0.0001
Observational data: associations, not effects.
Further findings
Association of sST2 with cardiac troponin I and NT-proBNP
- sST2 positively associated with cardiac troponin I
- P = 0.0001
- sST2 positively associated with N-terminal pro-brain natriuretic peptide
- P = 0.0001
sST2 in established IIM
- Established IIM had sST2 levels comparable to HC and RA patients
Original publication
Elevated sST2 associates with cardiac involvement and declines after treatment in newly diagnosed patients with idiopathic inflammatory myopathies. Arthritis Res Ther. Published 19 May 2026. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →